AMENDMENTAmendment Number One • February 13th, 2006 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances) • California
AMENDMENT NUMBER ONE (this “amendment”) dated February 7, 2006 (the “Effective Date”) to the Collaboration and License Agreement dated as of July 20, 2001 (the “Collaboration Agreement”) by and between Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130 (“Neurocrine”) and Glaxo Group Limited, Glaxo Wellcome House, Berkley Avenue, Greenford, Middlesex, England, U.K. UB 06 0NN (“GGL”)
